Hsbc Holdings PLC Reduces Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Hsbc Holdings PLC cut its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 43.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 524,814 shares of the biopharmaceutical company’s stock after selling 399,619 shares during the quarter. Hsbc Holdings PLC owned about 0.09% of Royalty Pharma worth $13,813,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in RPRX. Versant Capital Management Inc raised its position in shares of Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,043 shares during the last quarter. Gladius Capital Management LP acquired a new stake in shares of Royalty Pharma during the second quarter worth $32,000. Fidelis Capital Partners LLC purchased a new stake in shares of Royalty Pharma during the first quarter valued at $46,000. GAMMA Investing LLC increased its position in shares of Royalty Pharma by 172.5% in the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 1,037 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in Royalty Pharma by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 802 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group increased their price objective on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Morgan Stanley increased their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. Finally, UBS Group downgraded Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target on the stock. in a research report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Stock Down 1.6 %

RPRX stock opened at $27.54 on Monday. Royalty Pharma plc has a one year low of $25.20 and a one year high of $31.66. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The firm’s fifty day moving average is $28.00 and its 200 day moving average is $27.98. The firm has a market cap of $16.45 billion, a PE ratio of 20.55, a P/E/G ratio of 4.17 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. The firm had revenue of $537.00 million for the quarter, compared to analysts’ expectations of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period last year, the firm earned $0.85 EPS. On average, research analysts forecast that Royalty Pharma plc will post 4.04 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 13th. Stockholders of record on Friday, August 16th were given a dividend of $0.21 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.05%. Royalty Pharma’s dividend payout ratio (DPR) is 62.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.